Michelle Willicombe

Featured in: Favicon

nature.com Favicon

thelancet.com Favicon

asn-online.org Favicon

rcpjournal.org Favicon

onlinelibrary.wiley.com Favicon

clinmed.rcpjournal.org

Articles

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

May 8, 2024 | thelancet.com | Carl S. Goodyear |Amit Patel |Eleanor J. Barnes |Michelle Willicombe

SummaryThe humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully understood. The OCTAVE DUO trial aimed to determine the value of third vaccinations in a wide range of patients with primary and secondary immunodeficiencies.
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease - Nature Medicine

Jul 6, 2023 | nature.com | Eleanor J. Barnes |Carl S. Goodyear |Michelle Willicombe |Stefan Siebert |John A Snowden |Peter Kelleher | +3 more

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml−1).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →